NYSEARCA:PBEInvesco Dynamic Biotechnology & Genome ETF Stock Price, Forecast & News

Invesco Dynamic Biotechnology & Genome ETF's stock was trading at $45.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PBE shares have increased by 29.3% and is now trading at $59.33.
View which stocks have been most impacted by COVID-19.

Press coverage about PBE stock has been trending neutral on Saturday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Invesco Dynamic Biotechnology & Genome ETF earned a media sentiment score of 0.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Invesco Dynamic Biotechnology & Genome ETF.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Dynamic Biotechnology & Genome ETF investors own include Align Technology (ALGN), Pfizer (PFE), Activision Blizzard (ATVI), Intel (INTC), Micron Technology (MU), Boeing (BA), Mastercard (MA), Netflix (NFLX), NVIDIA (NVDA) and Visa (V).

Invesco Dynamic Biotechnology & Genome ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PBE."

Invesco Dynamic Biotechnology & Genome ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of America Corp DE (1.33%), Advisor Group Holdings Inc. (1.04%), Institute for Wealth Management LLC. (0.56%), Hills Bank & Trust Co. (0.41%), Loveless Wealth Management LLC (0.35%) and Steward Partners Investment Advisory LLC (0.33%).

PBE stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Gerber Kawasaki Wealth & Investment Management, Commonwealth Equity Services LLC, Raymond James Financial Services Advisors Inc., Bank of America Corp DE, Loveless Wealth Management LLC, HighTower Advisors LLC, and Jacobi Capital Management LLC.

PBE stock was purchased by a variety of institutional investors in the last quarter, including Baird Financial Group Inc., WBH Advisory Inc., Stifel Financial Corp, Captrust Financial Advisors, Flagship Harbor Advisors LLC, TCI Wealth Advisors Inc., NEXT Financial Group Inc, and Steward Partners Investment Advisory LLC.

Shares of PBE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBE stock can currently be purchased for approximately $59.33.

Invesco Dynamic Biotechnology & Genome ETF has a market capitalization of $231.39 million.

The official website for Invesco Dynamic Biotechnology & Genome ETF is www.invescopowershares.com.

Invesco Dynamic Biotechnology & Genome ETF's mailing address is 301 West Roosevelt Road, WHEATON, IL 60187, United States. The company can be reached via phone at +1-800-9830903.